Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis
Patients with CF showed evidence of persisting systemic inflammation despite ETI therapy, which may have long-term potentially adverse effects on respiratory and other organ systems.
Authors
- John A. Smith (ORCID: https://orcid.org/0000-0001-8837-4928)
- I. Waller
- Urszula Cytlak (ORCID: https://orcid.org/0000-0002-2536-6012)
- Robert Lord (ORCID: https://orcid.org/0000-0001-9008-2502)
- Rosemary E Maher (ORCID: https://orcid.org/0000-0002-2137-6619)
- Daniel Brice (ORCID: https://orcid.org/0000-0002-2507-3965)
- Eva Caamaño‐Gutiérrez (ORCID: https://orcid.org/0000-0001-7737-5941)
- Mark A. Travis (ORCID: https://orcid.org/0000-0002-8485-2272)
- Edward Emmott (ORCID: https://orcid.org/0000-0002-3239-8178)
- Peter Barry (ORCID: https://orcid.org/0000-0001-6326-4431)
- Alex Rothwell (ORCID: https://orcid.org/0000-0001-5690-9481)
- Kimberley Driver
- Paul McNamara (ORCID: https://orcid.org/0000-0002-7055-6034)
- Andrew Jones (ORCID: https://orcid.org/0000-0003-3232-1055)
- Dave Lee (ORCID: https://orcid.org/0000-0003-3367-5808)
- Saad Aleem
- Emily Smith
Institutions
- University of Liverpool (GB)
- Manchester Academic Health Science Centre (GB)
- Wellcome Centre for Cell-Matrix Research (GB)
- University of Manchester (GB)
- Manchester University NHS Foundation Trust (GB)
- Alder Hey Children's Hospital (GB)
Publication Details
- Journal
- Thorax
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1136/thorax-2024-222242
- Citations
- 6
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 9.11
Funders
- Wellcome Trust
- Medical Research Council